NCT04468984 | M20-178 | DRUG CO – Green Bay Oncology

Clinical Trial: NCT04468984 | M20-178 | DRUG CO

NCT Number: NCT04468984

Protocol ID: M20-178

Sponsor: DRUG CO

Disease Site: Blood Disorders-Other

Disease Category: Blood Disorders-Other

Detail: A Randomized, Open-Label, Phase 3 Study Evaluating Efficacy and Safety of Navitoclax in Combination with Ruxolitinib Versus Best Available Therapy in Subjects with Relapsed/Refractory Myelofibrosis (TRANSFORM-2)

For more details, click here.

Interested in participating in this trial?

Clinical Trial

First Name

Last Name

Phone

Preferred Contact Method:

Preferred Location:

Patient Type:

Current Patient New Patient

Interested in:

Cancer Clinical Trial Blood Disorder Clinical Trial

Disease Site:

Disease Category

What do all the numbers mean on clinical trials?

National Clinical Trial Identifier

The National Clinical Trial (NTC) is assigned by the National Library of Medicine when a new study appears in the clinical trials database.

ex: NCT0526225 | GY026 | NRG

PROTOCOL IDENTIFICATION NUMBER

Any unique identifier assigned to the protocol by the sponsor.

ex: NCT0526225 | GY026 | NRG

STUDY SPONSOR

A sponsor is an individual, institution, company or organization that takes the responsibility to initiate, manage and/or finance the clinical trial.

ex: NCT0526225 | GY026 | NRG